DMAC catalyst calendar

DiaMedica Therapeutics Inc.

Upcoming catalysts
2
Cash runway
14.4 months
Cash & investments
$44M
Phase 3 programs
1

DiaMedica Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 14.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 83% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 10, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Trial Milestone Phase 2/Phase 3

Track DMAC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open DMAC in the tracker

Recent history

DateEventTypePhase
August 10, 2026 Quarterly results filed (8-K) Earnings —
May 6, 2026 Quarterly results filed (8-K) Earnings —
March 31, 2026 Quarterly results filed (8-K) Earnings —
January 5, 2026 8-K filed: Other event Filing —
December 18, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 12, 2025 Quarterly results filed (8-K) Earnings —
August 12, 2025 Quarterly results filed (8-K) Earnings —
August 12, 2025 8-K filed: Material agreement Corporate —
August 6, 2025 8-K filed: Leadership change, Reg FD disclosure, Other event Corporate —
July 21, 2025 8-K filed: Material agreement, Other event Corporate —
July 17, 2025 8-K filed: Reg FD disclosure Filing —
May 13, 2025 Quarterly results filed (8-K) Earnings —
March 16, 2022 Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) Trial Milestone Phase 2
January 23, 2020 Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke Trial Milestone Phase 2
July 21, 2019 Study to Assess PK, Safety and Tolerability in Patients With DM and CKD Trial Milestone Phase 1
March 15, 2017 An Open Label, Phase 1b, Ascending Dose Study of DM199 Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.